12:07 PM EST - Lorus Therapeutics Inc. : announced that the United States Patent and Trademark Office has allowed Lorus' patent for its lead small molecule anticancer drug, LOR-253. The patent, which was originally set to expire in May 2026, was granted a patent term adjustment that extends the patent expiry date to February 2028. Lorus Therapeutics Inc.
shares T.LOR are trading unchanged at $0.21.
